Bailard’s Oramed Pharmaceuticals ORMP Stock Holding History

Bailard’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$152K	Hold	32,478	–	–	﹤0.01%	732
2026 Q2	$156K	Hold	32,478	–	–	﹤0.01%	746
2026 Q1	$110K	Buy	+32,478	New	+$110K	﹤0.01%	723

Other funds holding ORMP

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Bailard's ORMP Position: Q3 2026 in Review

Bailard held its Oramed Pharmaceuticals (ORMP) position steady in Q3 2026 at 32,478 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #732.

Bailard first reported a position in ORMP in Q1 2026 and has held it in 3 quarters since. The position peaked at $156K in Q2 2026. 5 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.

Bailard held 32,478 shares of Oramed Pharmaceuticals worth $152K as of Q3 2026.
Bailard left its Oramed Pharmaceuticals share count unchanged in Q3 2026.
Oramed Pharmaceuticals made up ﹤0.01% of Bailard's portfolio in Q3 2026, its #732 holding.
Bailard first reported a position in Oramed Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
Bailard's Oramed Pharmaceuticals position peaked at $156K in Q2 2026.
5 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.

Based on Bailard's 13F filing for Q3 2026, filed 13 Oct 2026.